Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Enters Biologics Arena With $325 Million Morphotek Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese firm plans to grow U.S. sales to $4 billion via expanded sales force of 1,500 by 2011, Eisai tells “The Pink Sheet” DAILY.

You may also be interested in...



Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody

Company hopes monoclonal antibody identified by NCI will demonstrate utility in multiple cancer types.

Morphotek’s Busy Year Continues With NCI Collaboration On Prostate Cancer Antibody

Company hopes monoclonal antibody identified by NCI will demonstrate utility in multiple cancer types.

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."

Related Content

Topics

UsernamePublicRestriction

Register

PS065792

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel